Compare VOC & PPBT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | VOC | PPBT |
|---|---|---|
| Founded | 2010 | 2010 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 49.0M | 45.3M |
| IPO Year | N/A | 2014 |
| Metric | VOC | PPBT |
|---|---|---|
| Price | $3.36 | $4.22 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 129.9K | 80.9K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 11.50% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $6.00 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.44 | $0.41 |
| 52 Week High | $3.74 | $5.18 |
| Indicator | VOC | PPBT |
|---|---|---|
| Relative Strength Index (RSI) | 58.81 | 77.72 |
| Support Level | $2.73 | $0.57 |
| Resistance Level | $3.48 | N/A |
| Average True Range (ATR) | 0.20 | 0.27 |
| MACD | 0.04 | 0.37 |
| Stochastic Oscillator | 51.70 | 79.88 |
VOC Energy Trust is a statutory trust. It is created to acquire and hold a term net profits interest for the benefit of the Trust unitholders. The underlying properties include VOC Brazos' net interests which are located in the states of Kansas and Texas. The trust is entitled to receive the net proceeds from the sale of production of oil and natural gas attributable to the underlying properties. The business and affairs of the Trust are managed by the Trustee, and neither VOC Brazos nor any of its affiliates has the ability to manage or influence the operations of the Trust.
Purple Biotech Ltd is a clinical-stage company focused on advancing first-in-class therapies to overcome tumor immune evasion and drug resistance, and to create treatments for people with cancer. Its oncology pipeline includes NT219: A dual inhibitor, small molecule that simultaneously targets Insulin Receptor Substrate 1 and 2 (IRS1/2) and Signal Transducer and Activator of Transcription (STAT3), two survival signal transduction pathways driving the development of cancer drug resistance. and CM24: is a humanized monoclonal antibody designed to block the interactions of Carcinoembryonic Antigen Related Cell Adhesion Molecule 1 (CEACAM1), a glycoprotein that plays a key role in immune regulation, cell adhesion, and tumor progression, CAPTN3.